Drug Eluting Stents In The Critically Ischemic Lower Leg (DESTINY)

Flanders Medical Research Program

Status and phase

Completed

Phase 2

Conditions

Peripheral Vascular Disease

Critical Limb Ischemia

Treatments

Device: MULTILINK VISION coronary stent system

Device: XIENCE V everolimus eluting coronary stent system

Study type

Interventional

Funder types

NETWORK

Identifiers

NCT00510393

FMRP-002

Details and patient eligibility

About

The Destiny trial compares the use of bare metal stent systems with drug eluting stent systems in the treatment of infrapopliteal lesions in patients with Critical Limb Ischemia. It will be investigated whether there is a difference in 12 month angiographic patency of the stented area using the 2 different stent systems.

Enrollment

140 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Stenotic (> 50%) or occlusive atherosclerotic disease of the infrapopliteal arteries
A maximum of two focal target lesions in one or more infrapopliteal vessels
Length of lesion is maximally 40 mm, allowing maximally 2 stents to be implanted
Reference vessel diameter should be 2-3.5 mm
Symptomatic critical limb ischemia (Rutherford 4, 5)
The patient must be > 18 years of age
Life-expectancy of more than 12 months
The patient has no child bearing potential or negative serum pregnancy test within 7 days of the index procedure
The patient must be willing and able to return to the appropriate follow-up times for the duration of the study
The patient must provide written patient informed consent that is approved by the ethics committee

Exclusion criteria

Patient refusing treatment
The reference segment diameter is not suitable for available stent design.
Unsuccessfully treated (>30% residual stenosis) proximal inflow limiting arterial stenosis
Untreatable lesion located at the distal outflow arteries
More than two infrapopliteal lesions in the same limb
Previously implanted stent(s) or PTA at the same lesion site
Lesion location requiring kissing stent procedure
Lesion lies within or adjacent to an aneurysm
Inflow-limiting arterial lesions left untreated
The patient has a known allergy to heparin, Aspirin or other anticoagulant/anti-platelet therapies or a bleeding diatheses or is unable, or unwilling, to tolerate such therapies.
The patient takes Phenprocoumon (Marcumar).
The patient has a history of prior life-threatening contrast media reaction.
The patient is currently enrolled in another investigational device or drug trial.
The patient is currently breast-feeding, pregnant or intends to become pregnant.
The patient is mentally ill or retarded.
Subject has received a heart transplant or any other organ transplant or is on a waiting list for any organ transplant
Subject is receiving or scheduled to receive anticancer therapy for malignancy within 30 days prior to or after the procedure
Subject is receiving immunosuppression therapy, or has known serious immunosuppressive disease (e.g., human immunodeficiency virus), or has severe autoimmune disease that requires chronic immunosuppressive therapy (e.g., systemic lupus erythematosus, etc.) The patient should also not receive inhibitors of CYP3A (such as Itraconazole, and Erythromycin), or inducers of CYP3A (such as Rifampin) within 90 days following the procedure.
Subject is receiving or is scheduled to receive chronic anticoagulation therapy (e.g., heparin, coumadin)
Use of alternative therapy (e.g. atherectomy, cutting balloon, laser, radiation therapy) as part of the index procedure